NASDAQ$RMTI

Rockwell Medical Inc · Q4 2019 earnings

Q4 2019 earnings · · Investor relations

Briefing

Reported positive adoption trends for Dialysate Triferic, highlighted by a 77% increase in clinics under contract, and signed a contract with a Medium-Sized Dialysis Organization (MDO) for Dialysate Triferic purchase, providing access to up to 160 clinics. Also, entered into exclusive license and supply agreements with Sun Pharma for Triferic commercialization rights in India.

Rockwell Medical reported a net loss of $7.3 million on net sales of $15.5 million for the fourth quarter of 2019. The company saw a decrease in net sales compared to the same period in 2018, but also a reduction in general and administrative expenses.

  • Net loss for Q4 2019 was $7.3 million, an improvement compared to a net loss of $9.4 million in Q4 2018.
  • Net sales for Q4 2019 were $15.5 million, a decrease from $16.9 million in Q4 2018.
  • Gross profit for Q4 2019 was approximately $1.1 million, compared to $1.2 million for Q4 2018.
  • Selling and marketing expenses increased by $1.6 million due to investments in the commercial platform for Triferic launch.

Headline financials

Total Revenue

$15.5M

Previous: $16.9M-8.1%
EPS (adj)

-$1.21

Previous: -$1.65+26.7%
Net Income

-$7.3M

No prior period
Operating Income

-$7M

No prior period
Gross Profit

$1.1M

No prior period

Revenue & EPS history

Rockwell Medical · Revenue · Quarterly

$15.5M

Q4 2019-8.1%vs Q4 2018
Beat estimate in 9 of 16 quarters(56%)
ActualEstimate

Forward guidance

Rockwell Medical expects adoption rates to accelerate through 2020 with the execution of sales, marketing, and medical education initiatives.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2019

Historical avgQ4 2019

-3.1%

Avg return

Earnings day

-3.3%

Avg return

5 days after

-3.0%

Avg return

30 days after

38%

24 / 63 earnings

Positive

+28.2%

Q3 2022

Best reaction

-43.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-13.0%-11.3%
Q1 2026-3.6%+2.8%-18.2%
Q3 2025-9.2%-17.1%-12.4%
Q1 2025-6.4%-9.8%-11.6%
Q4 2024-20.5%-31.8%-41.5%
Q3 2024-43.4%-49.2%-55.5%
Q2 2024+22.6%+35.6%+68.4%
Q1 2024+0.6%+4.1%+8.2%
Q4 2023+3.6%+0.0%-12.1%
Q3 2023+12.2%+5.1%-11.2%
Q2 2023-7.4%-25.8%-28.5%
Q1 2023-4.5%-3.7%+71.8%
Q4 2022+14.6%+18.4%+74.7%
Q3 2022+28.2%+19.4%+0.0%
Q2 2022+12.0%+7.1%-14.1%
Q1 2022+3.0%-17.3%-34.7%
Q4 2021-13.6%-11.4%-27.3%
Q3 2021-7.7%-7.7%-21.2%
Q2 2021-6.2%-10.8%-4.6%
Q1 2021-2.2%-4.3%+0.0%
Q4 2020+4.5%-1.8%-13.5%
Q3 2020+1.1%+5.6%+33.7%
Q2 2020+4.2%+0.0%-26.3%
Q1 2020-4.7%-12.9%-9.0%
Q4 2019-42.7%-25.0%-22.6%
Q3 2019+5.4%+12.4%+23.7%
Q2 2019-5.6%+2.0%+9.3%
Q1 2019-7.5%-11.9%-25.6%
Q4 2018+3.0%+23.9%+4.7%
Q3 2018+8.9%+12.3%-16.2%
Q2 2018-15.5%-12.4%-13.6%
Q1 2018-2.5%+5.8%-8.8%
Q4 2017-17.5%-18.3%-14.1%
Q3 2017+9.6%+11.6%+3.4%
Q2 2017-4.2%-1.5%-5.4%
Q1 2017-1.2%-9.1%+9.3%
Q4 2016+10.0%+10.2%+10.6%
Q3 2016-20.5%-3.5%+27.3%
Q2 2016-8.9%-8.1%-10.2%
Q1 2016+19.7%
Q4 2015-36.8%
Q3 2015-10.5%
Q2 2015+11.5%
Q1 2015+12.9%
Q4 2014-6.6%
Q3 2014+5.7%
Q2 2014+0.1%
Q1 2014-8.5%
Q3 2013-0.8%
Q2 2013+0.6%
Q1 2013-7.6%
Q4 2012-19.9%
Q3 2012-3.3%
Q2 2012-6.4%
Q1 2011-0.2%
Q1 2012+1.0%
Q4 2011-4.4%
Q3 2011-9.3%
Q3 2010-9.3%
Q2 2011-0.1%
Q2 2010-0.1%
Q4 2010-1.4%
Q1 2010+3.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro